BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Axon you shall receive: In enzyme-target bid, $30M series A cash fuels Disarm
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Axon you shall receive: In enzyme-target bid, $30M series A cash fuels Disarm
Sep. 20, 2017
By
Randy Osborne
No Comments
For scientists aiming to combat the long-known problem of axonal degeneration, "the issue was that there wasn't a lever to pull, there wasn't a drug target," Disarm Therapeutics Inc.'s acting CEO, Jason Rhodes, told BioWorld.
BioWorld